09/02/2026 – AB Science announced that the Food and Drug Administration (FDA) granted the status of Minor Use in Major Species (MUMS) for Masivet® in the treatment of canine mast cell tumors Download PDF Category: 20269 February 2026Post navigationPreviousPrevious post:AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancerNextNext post:AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALSRelated PostsAB Science web conference of October 14, 202614 October 2026Web conference on October 14, 2026, from 6:00 p.m. to 7:30 p.m.12 October 2026Revenues for the first half of 2026 and update on AB Science’s activities9 October 2026AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026
AB Science provides an update on its development plan and financial calendar following a sponsor Good Clinical Practice inspection29 September 2026
AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 202617 August 2026
AB Science announces the successful completion of capital increases of a total gross amount of EUR 14.2 million10 August 2026